The chairman of AstraZeneca has said the "tax-effective" structure of the proposed deal with Pfizer would have made it a "controversial" deal.
"It was possibly within the rules - we think so - but it was clearly a controversial deal," he told ITV News Business Editor Joel Hills.
Pfizer has until Monday until it admits defeat in bidding for AstraZeneca. But after the shenanigans of the past few days we cannot be sure.
AstraZeneca's share price is tumbling back down to earth after the board rejected a "final" Pfizer bid. So is the takeover really over?
Sweden's Finance Minister says the Government should be "very, very sceptical" about any promises the US pharmaceutical giant makes.